Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;31(6):1224-9.
doi: 10.2337/dc07-2013. Epub 2008 Feb 11.

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

Stephane De Wit  1 , Caroline A Sabin, Rainer Weber, Signe Westring Worm, Peter Reiss, Charles Cazanave, Wafaa El-Sadr, Antonella d'Arminio Monforte, Eric Fontas, Matthew G Law, Nina Friis-Møller, Andrew Phillips; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
Affiliations

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

Stephane De Wit et al. Diabetes Care. 2008 Jun.

Abstract

Objective: The aims of this study were to determine the incidence of diabetes among HIV-infected patients in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort, to identify demographic, HIV-related, and combination antiretroviral therapy (cART)-related factors associated with the onset of diabetes, and to identify possible mechanisms for any relationships found.

Research design and methods: D:A:D is a prospective observational study of 33,389 HIV-infected patients; diabetes is a study end point. Poisson regression models were used to assess the relation between diabetes and exposure to cART after adjusting for known risk factors for diabetes, CD4 count, lipids, and lipodystrophy.

Results: Over 130,151 person-years of follow-up (PYFU), diabetes was diagnosed in 744 patients (incidence rate of 5.72 per 1,000 PYFU [95% CI 5.31-6.13]). The incidence of diabetes increased with cumulative exposure to cART, an association that remained significant after adjustment for potential risk factors for diabetes. The strongest relationship with diabetes was exposure to stavudine; exposures to zidovudine and didanosine were also associated with an increased risk of diabetes. Time-updated measurements of total cholesterol, HDL cholesterol, and triglycerides were all associated with diabetes. Adjusting for each of these variables separately reduced the relationship between cART and diabetes slightly. Although lipodystrophy was significantly associated with diabetes, adjustment for this did not modify the relationship between cART and diabetes.

Conclusion: Stavudine and zidovudine are significantly associated with diabetes after adjustment for risk factors for diabetes and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that the two thymidine analogs probably directly contribute to insulin resistance, potentially through mitochondrial toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rates (per 1,000 PYFU) of new-onset diabetes stratified by years of exposure to cART (A) and stavudine (B).
See this image and copyright information in PMC

Comment in

  • HIV therapy and diabetes risk.
    Dagogo-Jack S. Dagogo-Jack S. Diabetes Care. 2008 Jun;31(6):1267-8. doi: 10.2337/dc08-0459. Diabetes Care. 2008. PMID: 18509145 No abstract available.

References

    1. Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD Data Collection on Adverse Events of Anti-HIV drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003. - PubMed
    1. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184. - PubMed
    1. Tien P, Schneider M, Cole S, Levine A, Cohen M, DeHovitz J, Young M, Justman J. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV study. AIDS. 2007;21:1739–1745. - PubMed
    1. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093–2100. - PubMed
    1. Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147–155. - PubMed

Publication types

Substances